neratinib
Working within I-SPY 2, the researchers identified a signature for determining whether patients are better candidates for anti-HER2 or immune checkpoint therapies.
Working within I-SPY 2, the researchers identified a signature for determining whether patients are better candidates for anti-HER2 or immune checkpoint therapies.